103 results about "Lungs metastasis" patented technology

The invention belongs to the cross technical field of nanomedicine, tumor treatment and immunotherapy, and particularly provides tumor mitochondria-targeted copper death selective induction nanoparticles, which are prepared by the following preparation method: S1, specifically coupling TPY and MHI through condensation reaction to obtain MTPY; s2, MTPY and copper ions are subjected to complexation, and an MTPY-Cu complex is obtained; and S3, the MTPY-Cu complex and albumin are subjected to self-assembly, and the MTPY-Cu-coated Alb nanoparticles are formed. The dosage of copper is only 1 / 1000 of that of free Cu < 2 + >, and equivalent immune regulation and killing effects can be achieved; primary tumors and distant tumor focuses can be inhibited, and lung metastasis is reduced; immune memory can be induced, and relapse can be prevented; the traditional Chinese medicine composition is combined with cis-platinum to remarkably enhance the curative effect and reverse the induced immunosuppression; the invention has the advantages of high biological safety and no obvious liver and kidney toxicity or hemolytic reaction.

The invention discloses a differentiated thyroid cancer lung metastasis risk prediction model construction method and system. 4D Label-free quantitative proteomics analysis and PRM and IHC dual verification are carried out on primary focus paraffin embedded tissue samples of lung metastatic DTC patients and non-lung metastatic DTC patients, and it is found that multiple key differential expression proteins DEPs may become potential biomarkers for predicting the DTC lung metastasis risk. In addition, the sample size is enlarged, three single and combined DTC lung metastasis risk prediction models are respectively constructed based on clinical features and key DEPs expression, then internal verification is performed on the efficiency of the three fitted models, and the optimal model is taken to construct Nomogram. According to the method, help is provided for risk stratification of lung metastasis of DTC patients, and an important basis is provided for formulating clinical individualized treatment schemes and follow-up visit strategies for high-risk patients.

The invention relates to a multifunctional silica plastid integrating chemotherapy, immunotherapy and gas therapy, and relates to a preparation method of the multifunctional silica plastid and application of the multifunctional silica plastid in tumor diagnosis and treatment. The schematic diagram is as shown in the figure, the membrane components comprise conventional phospholipid and complex lipid, a chemotherapeutic drug doxorubicin (DOX) entrapped on a hydrophilic core and Fe3 (CO) 12 entrapped on a hydrophobic core, and the chemotherapeutic drug can be adjusted according to needs and is suitable for broad-spectrum tumor treatment. The drug-loaded silica plastid can generate part of carbon monoxide in a tumor high-concentration hydrogen peroxide (H2O2) environment and release internally-loaded chemotherapeutic drugs. Under the action of ultrasound (US), the multifunctional silicon plastid can realize fixed-point release of chemotherapeutic drugs DOX and carbon monoxide at a tumor site, the enrichment and uptake of the drugs at the tumor site are greatly improved, in addition, the system is combined with the alphaPD-L1 antibody, the immunosuppressive PD-L1 / PD-1 axis can be blocked, T cells are recruited to attack tumors, meanwhile, the immunosuppressive regulatory T cells (Tregs) are reduced, and the tumor treatment effect is improved. The tumor inhibition can be enhanced; the pulmonary metastasis can be obviously reduced.

The invention relates to a construction method and application of a postoperative II-III stage colorectal cancer long-term lung metastasis prediction model, and belongs to the technical field of machine learning. The construction method of the postoperative early colorectal cancer long-term pulmonary metastasis prediction model comprises the following steps: screening through machine learning and a logistic step-by-step backward regression method to obtain four indexes formed by combined prediction of postoperative early colorectal cancer long-term pulmonary metastasis, and presenting the prediction model through a combined diagnosis equation and a column diagram; the four indexes for predicting the long-term lung metastasis formation of the postoperative early colorectal cancer comprise baseline ctDNA, serum carcino-embryonic antigen, cancer nodule and plasma PIK3CA gene. The model constructed by the invention is the first model for predicting the long-term lung metastasis probability of the patient with the early colorectal cancer, and the ROC of the model is superior to that of each element in the model.

The invention discloses application of SHC3 as a diagnosis and prognosis marker and a treatment target of lung metastasis of breast cancer. The research shows that the expression of SHC3 in TNBC lung metastatic cells is remarkably up-regulated, and the up-regulation is closely related to the prognosis of TNBC patients; the increase of SHC3 expression is positively correlated with the migration ability of the TNBC cells, which proves that the SHC3 gene is obviously up-regulated in the TNBC cells of pneumophilic metastasis and can be used as a biomarker of lung metastasis of breast cancer; researches show that silence of SHC3 can significantly weaken the metastasis ability of TNBC and reduce the number of pulmonary metastasis nodules, overexpression of SHC3 can enhance the metastasis activity of TNBC, and SHC3 can be used as a therapeutic target of breast cancer pulmonary metastasis; the invention provides a new marker for prognosis of breast cancer and diagnosis of lung metastasis of breast cancer, and provides a new target and treatment strategy and direction for treatment of lung metastasis of breast cancer.

The invention discloses a biomarker combination for predicting lung metastasis of breast cancer and application of the biomarker combination. The biomarker combination for predicting lung metastasis of breast cancer comprises MUC16, MAP3K13, NR4A3, FAM111A, ZNF562 and NRP1. According to the invention, a GEO database and a TCGA database are combined, a biomarker combination for predicting lung metastasis of breast cancer is obtained through analysis and screening, and potential gene characteristics closely related to development of lung metastasis of breast cancer patients are further determined by analyzing expression levels of six biomarker genes and interaction with a tumor environment. And a more effective and personalized tool is provided for prediction and treatment of breast cancer.

The application belongs to the technical field of biotechnology and gene therapy, and particularly relates to application of SNIP1 protein as a target in preparation or screening of an antitumor drug. The application finds that the SNIP1 protein is a non-histone substrate of lysine methyltransferase KMT5A, which promotes breast cancer cell growth, invasion and lung metastasis through KMT5A-mediated K301 monomethylation; therefore, the SNIP1 protein can be used as a target for screening of an antitumor drug, and a drug obtained by screening and inhibiting methylation of the K301 site of the SNIP1 protein can be used for antitumor; and the application provides a polypeptide specifically combined with the K301 site of the SNIP1 protein, the polypeptide is combined with the K301 site of the SNIP1 protein, inhibits methylation of the SNIP1 protein, and finally can inhibit tumor growth, proliferation, invasion and metastasis, and can be used as a new targeted antitumor drug.

The invention relates to the technical field of tumor marker detection, in particular to a breast cancer lung metastasis related biomarker screening system which comprises a differential genetic factor mining module, a function association module, a verification screening module, an interference elimination module and an optimization integration module. According to the method, the candidate genetic factors highly associated with lung metastasis are extracted, and the expression fluctuation characteristics are combined to carry out difference analysis, so that the preliminary screening accuracy is improved, pathological information and pathway annotation are integrated to construct an action network, pathway weights are analyzed, and functional expressions of the candidate factors are quantitatively evaluated; an independent sample is called to verify transcription consistency and clinical relevance, interference factors with poor repeatability are eliminated, non-tumor tissue high-expression interference items are rejected in combination with background transcription characteristics, the specificity and adaptability of screening results are improved, and finally a marker set with metastasis mechanism indicating significance and prognosis prediction value is formed through comprehensive evaluation. And clinical transformation support is provided for identification of lung metastasis of breast cancer.

This invention relates to the application of β-sitosterol glycoside in the preparation of products for treating lung cancer. This invention creatively provides a new use for the active monomer β-sitosterol glycoside, demonstrating that β-sitosterol glycoside can significantly inhibit the migration ability of lung cancer cells at doses without cell proliferation inhibitors, clarifying the specificity of its anti-metastatic effect, and laying the foundation for further new drug development of this monomer component. Through an in vivo mouse lung metastasis model, this invention demonstrates that β-sitosterol glycoside effectively inhibits the formation of lung metastases while exhibiting no significant toxic side effects in experimental animals, demonstrating high safety, and providing a new candidate molecule for the development of low-toxicity, highly effective anti-lung cancer metastasis drugs.

The application belongs to the technical field of nanomedicine, tumor treatment and immunotherapy, and specifically provides a copper death selective induction nanoparticle targeting tumor mitochondria, which is prepared by the following preparation method: S1, TPY is specifically coupled with MHI through a condensation reaction to obtain MTPY; S2, MTPY is complexed with copper ions to obtain an MTPY-Cu complex; and S3, the MTPY-Cu complex is self-assembled with albumin to form an MTPY-Cu@Alb nanoparticle. The copper dose of the application is only 1 / 1000 of that of free Cu 2+ , and the equivalent immune regulation and killing effects can be achieved; the primary tumor and distant tumor foci can be inhibited, and lung metastasis can be reduced; and the application can induce immune memory and prevent recurrence; the application is combined with cisplatin to significantly enhance the therapeutic effect and reverse the induced immunosuppression; and the application has high biological safety, and has no obvious hepatorenal toxicity or hemolytic reaction.

The invention discloses application of ginsenoside Rc and a derivative or salt thereof in preparation of a medicine for preventing and / or treating early lung metastasis of Lewis lung cancer and / or combining other tumors. The ginsenoside Rc shows a better effect of preventing and treating early lung metastasis of Lewis lung cancer and higher safety than cis-platinum in a tumor-bearing mouse model, and no adverse reaction is found.

The invention discloses a mouse liver cancer cell line with a high lung metastasis characteristic as well as a construction method and application thereof, and belongs to the technical field of biology and oncology. The cell is preserved in China Center for Type Culture Collection on February 4, 2026, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: C202621. The PNV-LM3 cell line provided by the invention is constructed by combining a PTEN KO and NRAS G12V mutated hydrodynamic tail vein injection model with tail vein injection in-vivo domestication, a mouse liver cancer model is successfully induced to generate lung metastasis, and the lung metastasis tendency of the cell line is greatly enhanced. Compared with a traditional Hepa1-6 cell line, the PNV-LM3 cell line has the advantages that the lung metastasis process of the liver cancer is more accurately and efficiently reproduced, and a more real experimental platform is provided for research of a liver cancer metastasis mechanism.

The application provides a combined drug, a liposome, a biomimetic liposome, a preparation method of the combined drug, the liposome and the biomimetic liposome, and application of the combined drug, the liposome and the biomimetic liposome in preparation of an anti-breast cancer lung metastasis drug, and belongs to the technical field of biological medicines. The combined drug comprises panatinib and ginsenoside Rg3. The application further provides a liposome PNT-Rg3-Lipo for simultaneously loading the two, and a biomimetic liposome MM / PNT-Rg3-Lipo coated with a macrophage membrane. Experiments show that the combination of the two can synergistically regulate chemokines CXCL1 , CXCL2 and CXCL11 , and the effect is better than the sum of the single use. The MM / PNT-Rg3-Lipo has uniform particle size, retains integrin alpha 4 / beta 1 functional proteins, can target lung metastases, significantly reduces metastatic nodules, and has good biocompatibility. The application provides an effective new strategy for resisting breast cancer lung metastasis.

The invention belongs to the technical field of anti-tumor drugs, and particularly relates to a flexible drug-loaded cell microparticle capable of efficiently targeting tumors and a preparation method of the flexible drug-loaded cell microparticle. Comprising tumor cell-derived drug-loaded microparticles coated with chemotherapeutic drugs, and a flexible regulator modified on the surfaces of the tumor cell-derived drug-loaded microparticles, the flexible regulator comprises a saponin compound and / or a steroid compound, and can regulate and control the hardness of the tumor cell-derived drug-loaded microparticles. The tumor cell-derived drug-loaded microparticles are modified, so that the enrichment and deep penetration of the drug-loaded microparticles in tumor tissues can be remarkably improved, and the efficient targeted delivery of the tumor tissues is realized. Meanwhile, efficient uptake of tumor stem cells to the medicine is promoted, targeted killing is achieved, the tumor stem cells are effectively removed, and tumor growth is remarkably inhibited. In addition, circulating tumor cells can be efficiently targeted, accurate delivery of tumor metastasis is achieved, and tumor metastasis is remarkably inhibited by inhibiting migration and invasion of tumor cells and reducing formation of lung metastasis.

The application belongs to the technical field of biological medicine, and particularly relates to a nucleic acid aptamer targeting MOTS-c and application thereof. The target sequence of the aptamer is SEQ ID NO:1, and the sequence of the nucleic acid aptamer is SEQ ID NO:2. The aptamer has good affinity with MOTS-c, can significantly inhibit the stemness characteristics of cancer cells by treating the cancer cells, significantly improve the lung metastasis of tumor-bearing mice, has good blocking effect on MOTS-c in vivo and in vitro, and has a certain anti-tumor metastasis treatment effect.

The present invention discloses a nanoparticle for dual-targeted treatment of breast cancer, and its preparation method and application. The nanoparticle for dual-targeted treatment of breast cancer uses polysaccharide-cholesterol hemisuccinate amphiphilic conjugate of Dendrobium officinale as a drug carrier to encapsulate anti-breast cancer chemotherapeutic drugs, and the surface of the drug carrier is modified with folic acid ligands. By using polysaccharide of Dendrobium officinale with immunomodulatory activity as a carrier and combining with folic acid ligands with active targeting function, the present invention realizes dual-targeting of breast cancer and exerts the effect of chemoimmunotherapy. After the prepared nanoparticles are delivered to solid tumors through passive and active targeting, the tumor cells are killed by the released chemotherapeutic drug (doxorubicin), and the immunogenic cell death (ICD) is enhanced by polysaccharide of Dendrobium officinale, promoting the proliferation of natural killer cells (NK cells), stimulating the maturation of dendritic cells, and coordinately regulating various immune cells, while preventing breast cancer lung metastasis.

The invention discloses application of HSF1A in preparation of a medicine for resisting lung cancer metastasis, and relates to the technical field of anti-tumor medicines. It is found for the first time that HSF1A can be used for inhibiting non-small cell lung cancer metastasis. The HSF1A is specifically combined with a CCT1 subunit ATPase structural domain of a TRIC / CCT compound, so that the protein folding function of the TRIC / CCT compound is interfered, and three key transfer promoting signal channels including YAP, STAT3 and mTOR are inhibited at the same time. In a pulmonary metastatic tumor model constructed by mouse tail intravenous injection, the formation of pulmonary metastatic tumor is obviously reduced by the HSF1A, and the fact that the HSF1A also has strong anti-metastatic capability in an in-vivo environment is proved; the safety is high, and the development and utilization prospects are good. The invention not only provides a new application of the HSF1A, but also provides a new thought and method for adjuvant therapy of cancers.

The invention belongs to the technical field of new applications of medicines, and particularly relates to an aniline pyridine TEAD degradation agent, a preparation method thereof and an application of the degradation agent in preparation of antitumor drugs. According to the research, a novel aniline pyridine TEAD degradation agent with a clear structure is designed and synthesized by coupling a TEAD palmitoylation inhibitor niflumic acid serving as a lead compound with a CRBN type E3 ligase ligand through connecting chains with different lengths and different types by virtue of a computer-aided drug design means. The influence of the optimal compound (XY-3L) on cancer cell proliferation and cell functions is detected in an in-vitro cell experiment, and the curative effect of the optimal compound (XY-3L) in a melanoma lung metastasis model is explored in vivo.

The invention relates to a screening method of anti-breast cancer key targets of a traditional Chinese medicine composition for treating triple-negative breast cancer pulmonary metastasis, which sequentially comprises the following steps: component-target preliminary screening, two sample Mendel randomization, SMR and co-localization, full phenotype association and side effect evaluation, pathway enrichment, clinical expression verification, molecular docking verification and the like. After Mendel randomization (MR) and SMR are placed in network pharmacology, population genetic variation is used as a natural randomization tool, evidence of causal relationship between exposure (target level) and outcome (breast cancer risk) is provided on a public GWAS level, traditional association analysis mixing and reverse causal risk are reduced, and the false positive rate of network pharmacology prediction is greatly reduced; pheWAS-MR is introduced to perform system identification on phenotypes of various diseases, so that a potential off-target effect can be identified in advance, the multiple effects and possible adverse reactions of potential treatment targets in traditional Chinese medicine compound targets can be evaluated, powerful data support is provided for subsequent clinical test design and drug alert strategies, and the risk of later failure of research and development is effectively reduced.

The present application relates to the application of long-chain non-coding RNA HILAR inhibitor in the preparation of drugs for preventing or / and treating lung adenocarcinoma metastasis. The present application provides specific intervention means for HILAR, and verifies the effectiveness of inhibiting lung adenocarcinoma metastasis: after the expression of HILAR is targeted and silenced in vitro by small interfering RNA technology, the invasion ability of lung adenocarcinoma cells is significantly inhibited, and the metastasis phenotype is obviously reversed; more importantly, through the delivery of short hairpin RNA by adeno-associated virus vector, the formation and development of lung metastasis are effectively reduced in a lung adenocarcinoma metastasis mouse model, and the in vivo imaging shows that the tumor luminescence signal intensity of the experimental group is continuously lower than that of the control group, and the overall survival condition of the animal is improved.

The invention belongs to the technical field of drug delivery and tumor immunotherapy, and particularly relates to an oncolytic virus vesicle as well as a preparation method and application thereof. The preparation method comprises the following steps: co-incubating oncolytic adenovirus and platelets in a buffer system containing prostaglandin E2, and inducing to form an inner membrane encapsulation body; and activating and releasing the vesicles under the conditions of 36-38 DEG C and 4-6% CO2, and carrying out gradient centrifugal collection of 300g, 2000g, 10000g and 100000g. The particle size of the oncolytic virus-loaded vesicle is 50-200nm, the surface of the oncolytic virus-loaded vesicle contains CD41, CD61 and P-selectin, and the oncolytic virus-loaded vesicle can realize long circulation and lung targeting delivery of oncolytic viruses, is suitable for preparing drugs for treating breast cancer and breast cancer lung metastasis, and has a remarkable tumor inhibition effect.

The invention relates to the technical field of biological medicines, and particularly discloses a nanocapsule SMCPM and application thereof in medicines for treating or preventing osteosarcoma and pulmonary metastasis. The SMCPM is composed of a photosensitizer Ce6 carried by mesoporous silicon oxide-manganese oxide particles, an NRF2 inhibitor ML385 and an OS targeting peptide PT-7. Experiments prove that the SMCPM is high in penetrating power and strong in cell killing effect; by down-regulating NRF2 expression and reversing nuclear translocation, a biochemical inhibitory microenvironment can be effectively repaired, the tolerance of cells to active oxygen and epithelial-mesenchymal transition activated and induced by a NOTCH1 signal axis are remarkably reduced, the oxidative stress level of the cells is enhanced, and PIT-induced immunogenic cell death is promoted; the released Mn < 2 + > and double-stranded DNA can regulate and control an immunosuppressive microenvironment by activating an STING pathway in cells, thereby inhibiting the growth of osteosarcoma and preventing lung metastasis.

The present invention discloses an application of RARRES2 gene in the diagnosis and treatment of brain metastasis of breast cancer. We first compared the gene expression differences between primary tumors of human breast cancer and brain metastases by mining public databases such as GEO and MET500, screened and compared the RARRES2 gene, and compared the expression of the RARRES2 gene in breast cancer bone metastasis, lung metastasis and liver metastasis. Secondly, single-cell transcriptome sequencing was performed on brain metastases of breast cancer patients. The results showed that the expression level of RARRES2 in brain metastasis of breast cancer was significantly lower than that in primary tumors, but the expression of RARRES2 in bone, lung and liver metastases of breast cancer was not significantly different from that in primary tumors, suggesting that it is specifically related to brain metastasis of breast cancer. By constructing RARRES2 overexpression and knockdown human breast cancer brain metastasis cell (MDA-MB-231) lines, it was found that RARRES2 overexpression significantly inhibited the proliferation and invasion of the cells. By constructing a luciferase-labeled RARRES2 overexpression breast cancer brain metastasis mouse model, it was found that RARRES2 overexpression can significantly inhibit the proliferation of breast cancer cells in the brain.

The invention relates to application of a dry memory T cell in preparation of a medicine for treating colorectal cancer pulmonary metastasis, and belongs to the technical field of biological medicine. The invention firstly proves that the capability of differentiating the Tscm cells into effector killer T cells can be effectively improved by knocking out the Erbin genes in the Tscm cells in a mouse body, lung metastasis of colorectal cancer is inhibited, and the treatment effect of CAR-T cells can be enhanced by the Tscm cells with the Erbin genes knocked out. In addition, xanthine is detected for many times in a mouse colorectal cancer lung metastasis focus after the Erbin gene in the Tscm cell is knocked out, hypoxanthine can promote generation of more Tscm cells in the tumor metastasis focus, and the Tscm cells are differentiated to generate killer T cells, so that colorectal cancer lung metastasis is inhibited. The metabolic pathway of hypoxanthine is further studied, it is found that allopurinol can inhibit conversion of hypoxanthine into xanthine and uric acid, and it is found that allopurinol can also inhibit colorectal cancer lung metastasis by injecting allopurinol into a colorectal cancer lung metastasis mouse model.

The invention belongs to the technical field of biological medicines, and provides application of combination of nicotinic acid and metformin in blocking the progress of esophageal squamous carcinoma. The invention discovers that nicotinic acid and metformin inhibit FRMD8 expression through different mechanisms for the first time so as to inhibit a JAK1-STAT3 signal channel. Nicotinic acid and metformin are combined to achieve a more remarkable inhibition effect on the ability of esophageal squamous cell carcinoma cells to subcutaneously grow in mice and generate pulmonary metastasis through caudal veins than a single drug, and a brand new drug direction is provided for prevention and treatment of esophageal squamous cell carcinoma.

The invention discloses an application of CD177 in treatment of lung metastasis of melanoma. The invention provides an application of CD177 as a target spot in screening of drugs for treating pulmonary metastasis of melanoma, an application of a CD177 inhibitor or a CD177 antibody in preparation of drugs for treating pulmonary metastasis of melanoma, and an application of a reagent for detecting CD177 in preparation of prognosis diagnosis tools for pulmonary metastasis of melanoma. Research finds that CD177 is highly expressed on neutrophil of a melanoma pulmonary metastasis focus, tumor infiltration of the neutrophil is remarkably inhibited by deletion of CD177, the progress of neutrophil-mediated mouse melanoma pulmonary metastasis is inhibited, and a CD177 monoclonal antibody can relieve the lung metastasis process of the melanoma. The invention provides a new target and a new treatment strategy for treatment of pulmonary metastasis of melanoma.

The application belongs to the field of biological pharmacy, and particularly relates to application of a Caerin polypeptide combined with a dendritic cell vaccine in preparation of a drug for treating breast cancer. The application finds that F1 / F3 significantly inhibits proliferation of 4T-1 cells and induces cell death in vitro, significantly inhibits growth of a primary tumor, reduces lung metastasis, and prolongs overall survival in vivo, and inoculation of a DC vaccine loaded with a tumor-related antigen can reduce tumor growth and enhance T cell activation in draining and non-draining lymph nodes. Compared with a vaccine loaded with a whole antigen (DCV1), a DC vaccine (DCV2) combined with F1 / F3 induced 'programmed death antigen' exhibits stronger anti-tumor activity, although TNF-alpha and IL-12 secretion thereof is lower. Therefore, the application combines the F1 / F3 polypeptide with the DCV2 to prepare a drug for treating breast cancer, effectively improves the treatment effect on the tumor, and highlights the importance of a combined immunotherapy strategy.

The invention discloses a hypoxia activating peptide-photosensitizer-drug conjugate and a preparation method and application thereof in the technical field of medicine, the conjugate takes indocyanine with a high molar extinction coefficient as a photosensitive core, distorted conjugate units are introduced to two sides of indole, the characteristic of'limited movement in molecules' is given to the conjugate, and radiation and non-radiation energy dissipation are balanced. Meanwhile, an azo bond sensitive to hypoxia is reasonably introduced between a light treatment module and a chemotherapy module to serve as a responsive linker, and is further coupled with two-molecule integrin targeting peptide cRGD, so that the azo bond is self-assembled into nanospheres in an aqueous solution, and a triple targeting mechanism, namely multivalent integrin receptor targeting, aggregation and tumor microenvironment hypoxia selective activation, is realized. In an in-situ osteosarcoma mouse model, the conjugate realizes real-time near-infrared two-region imaging, shows potent tumor inhibition, effectively inhibits lung metastasis, and does not detect obvious systemic toxicity.

The invention discloses a method for preventing lung relapse of cancer by using a cis-platinum lipid complex, and particularly discloses application of an inhalation type cis-platinum lipid complex (ILC) in preparation of a medicine for preventing or delaying osteosarcoma lung metastasis postoperative relapse or primary lung cancer postoperative relapse.